Interaction reference
GLP-1 receptor agonists with Alcohol
No pharmacokinetic interaction with GLP-1s, but alcohol tolerance often drops noticeably on GLP-1 therapy. Many readers report it as the most surprising effect.
You will probably feel alcohol much faster on a GLP-1 — start lower than your pre-treatment baseline.
Per-GLP-1 breakdown
- Wegovysemaglutide 2.4 mgMonitor
Mechanism: GLP-1s blunt the reward/craving response to alcohol and slow gastric emptying. Combined effect: lower consumption AND amplified subjective effect per drink.
What to do: Reduce starting dose by half until you know your new tolerance. Hypoglycemia risk increases if combined with sulfonylureas or insulin.
- ZepboundtirzepatideMonitor
Mechanism: GLP-1s blunt the reward/craving response to alcohol and slow gastric emptying. Combined effect: lower consumption AND amplified subjective effect per drink.
What to do: Reduce starting dose by half until you know your new tolerance. Hypoglycemia risk increases if combined with sulfonylureas or insulin.
- OzempicsemaglutideMonitor
Mechanism: GLP-1s blunt the reward/craving response to alcohol and slow gastric emptying. Combined effect: lower consumption AND amplified subjective effect per drink.
What to do: Reduce starting dose by half until you know your new tolerance. Hypoglycemia risk increases if combined with sulfonylureas or insulin.
- MounjarotirzepatideMonitor
Mechanism: GLP-1s blunt the reward/craving response to alcohol and slow gastric emptying. Combined effect: lower consumption AND amplified subjective effect per drink.
What to do: Reduce starting dose by half until you know your new tolerance. Hypoglycemia risk increases if combined with sulfonylureas or insulin.
- FoundayoorforglipronMonitor
Mechanism: GLP-1s blunt the reward/craving response to alcohol and slow gastric emptying. Combined effect: lower consumption AND amplified subjective effect per drink.
What to do: Reduce starting dose by half until you know your new tolerance. Hypoglycemia risk increases if combined with sulfonylureas or insulin.
Sources
- Self-reported alcohol consumption on GLP-1 therapy (opens in a new tab) — Journal of Clinical Endocrinology and Metabolism